Improving vitreoretinal surgery

Article

Treating the aetiology of recurrent vitreous haemorrhage improves patient outcomes

However, treatment options to deal with the factors associated with RVH after PPV do not address the aetiology of the problem or provide a cure. "Accordingly, there is no current consensus about the treatment of choice for these patients," added Drs Nadal and Carreras. "We believe that the results of our study could contribute to the improvement of two important factors in vitreoretinal surgery!"

"Our approach was based on direct treatment of the aetiology through eliminating the neovessels at the sclerotomy site and avoiding recurrence," said Drs Nadal and Carreras.

In eyes with sclerotomy site neovascularization, fibrovascular tissue can grow around the old incisions. This is as a result of a hypoxic response to peripheral retinal ischaemia and can favour movement of episcleral vessels through the sclerotomy site.

"Sclerotomies with incarcerated vitreous provide scaffold for ingrowing episcleral vessels eventually leading to new vessels being formed and recurrent vitreous haemorrhage occurring," they continued. "We proposed removal of any scaffold for neovascular growth by diathermy of sclerotomy site neovessels and ablation of existing retinal ischaemic tissue, which reduces hypoxic and/or angiogenic stimuli."

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.